epoetin-alfa and Alzheimer-Disease

epoetin-alfa has been researched along with Alzheimer-Disease* in 2 studies

Other Studies

2 other study(ies) available for epoetin-alfa and Alzheimer-Disease

ArticleYear
Therapeutic Effect of Erythropoietin on Alzheimer's Disease by Activating the Serotonin Pathway.
    International journal of molecular sciences, 2022, Jul-24, Volume: 23, Issue:15

    Alzheimer’s disease (AD) is a neurodegenerative disease characterized by memory impairment in patients. Erythropoietin (EPO) has been reported to stimulate neurogenesis. This study was conducted to determine the regenerative effects of EPO in an AD model and to assess its underlying mechanism. Recombinant human EPO was intraperitoneally administered to AD mice induced by intracerebroventricular Aβ oligomer injection. Behavioral assessments with novel object recognition test and passive avoidance task showed improvement in memory function of the EPO-treated AD mice compared to that of the saline-treated AD mice (p < 0.0001). An in vivo protein assay for the hippocampus and cortex tissue indicated that EPO treatment modulated neurotransmitters, including dopamine, serotonin, and adrenaline. EPO treatment also restored the activity of serotonin receptors, including 5-HT4R, 5-HT7R, and 5-HT1aR (p < 0.01), at mRNA levels. Furthermore, EPO seemed to exert an anti-inflammatory influence by downregulating TLR4 at mRNA and protein levels (p < 0.05). Finally, an immunohistochemical assay revealed increments of Nestin(+) and NeuN(+) neuronal cells in the CA3 region in the EPO-treated AD mice compared to those in the saline-treated AD mice. The conclusion is that EPO administration might be therapeutic for AD by activating the serotonergic pathway, anti-inflammatory action, and neurogenic characteristics.

    Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Disease Models, Animal; Epoetin Alfa; Erythropoietin; Hippocampus; Humans; Mice; Neurodegenerative Diseases; Recombinant Proteins; RNA, Messenger; Serotonin

2022
Functional outcomes of anemia in older adults.
    Seminars in hematology, 2008, Volume: 45, Issue:4

    Observational studies have consistently documented independent, strong associations of anemia--even if not severe--with major adverse functional outcomes in older adults. In this chapter, recent epidemiologic evidence linking mild anemia with decline in physical and cognitive function, frailty, and disability in community-dwelling older adults is reviewed. Altogether, these biologically plausible associations provide empirical, though not conclusive, support for the notion of mild anemia as a cause of adverse functional outcomes in older adults. Randomized clinical trial data assessing the impact of anemia correction on functional outcomes are lacking at this time.

    Topics: Activities of Daily Living; Adult; Aged; Aging; Alzheimer Disease; Anemia; Cognition; Epoetin Alfa; Erythropoietin; Female; Frail Elderly; Hematinics; Hemoglobins; Humans; Male; Physical Fitness; Recombinant Proteins

2008